BioRestorative Therapies Inc - ESG Rating & Company Profile powered by AI
Scroll down to the end of the webpage for potential risks for BioRestorative Therapies Inc based on sector, location and marketcap. The assessment of BioRestorative Therapies Inc was assembled by All Street Sevva using cutting edge AI. The report of BioRestorative Therapies Inc employs data from across the internet as well as from public documents by BioRestorative Therapies Inc.
BioRestorative Therapies Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 4.0, social score of 0.0 and governance score of 8.0.
4.0
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
989 | Spectrum Pharmaceuticals Inc | 4.1 | High |
989 | Tricida Inc | 4.1 | High |
1004 | BioRestorative Therapies Inc | 4.0 | High |
1004 | Can B Corp | 4.0 | High |
1004 | CLS Holdings USA Inc | 4.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does BioRestorative Therapies Inc have an accelerator or VC vehicle to help deliver innovation?
Does BioRestorative Therapies Inc disclose current and historical energy intensity?
Does BioRestorative Therapies Inc report the average age of the workforce?
Does BioRestorative Therapies Inc reference operational or capital allocation in relation to climate change?
Does BioRestorative Therapies Inc disclose its ethnicity pay gap?
Does BioRestorative Therapies Inc disclose cybersecurity risks?
Does BioRestorative Therapies Inc offer flexible work?
Does BioRestorative Therapies Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does BioRestorative Therapies Inc disclose the number of employees in R&D functions?
Does BioRestorative Therapies Inc conduct supply chain audits?
Does BioRestorative Therapies Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does BioRestorative Therapies Inc conduct 360 degree staff reviews?
Does BioRestorative Therapies Inc disclose the individual responsible for D&I?
Does BioRestorative Therapies Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does BioRestorative Therapies Inc disclose current and / or historical scope 2 emissions?
Does BioRestorative Therapies Inc disclose water use targets?
Does BioRestorative Therapies Inc have careers partnerships with academic institutions?
Did BioRestorative Therapies Inc have a product recall in the last two years?
Does BioRestorative Therapies Inc disclose incidents of discrimination?
Does BioRestorative Therapies Inc allow for Work Councils/Collective Agreements to be formed?
Has BioRestorative Therapies Inc issued a profit warning in the past 24 months?
Does BioRestorative Therapies Inc disclose parental leave metrics?
Does BioRestorative Therapies Inc disclose climate scenario or pathway analysis?
Does BioRestorative Therapies Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does BioRestorative Therapies Inc disclose the pay ratio of women to men?
Does BioRestorative Therapies Inc support suppliers with sustainability related research and development?
Does BioRestorative Therapies Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does BioRestorative Therapies Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is BioRestorative Therapies Inc involved in embryonic stem cell research?
Does BioRestorative Therapies Inc disclose GHG and Air Emissions intensity?
Does BioRestorative Therapies Inc disclose its waste policy?
Does BioRestorative Therapies Inc report according to TCFD requirements?
Does BioRestorative Therapies Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does BioRestorative Therapies Inc disclose energy use targets?
Does BioRestorative Therapies Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does BioRestorative Therapies Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for BioRestorative Therapies Inc
These potential risks are based on the size, segment and geographies of the company.
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.